Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-12-25
2007-12-25
Ungar, Susan (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S134100, C424S138100, C424S141100, C424S143100, C424S152100, C424S178100
Reexamination Certificate
active
10685665
ABSTRACT:
The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds α5β1 integrin, and detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual; methods of reducing or inhibiting angio genesis in a tissue in an individual; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition.
REFERENCES:
patent: 5627263 (1997-05-01), Rouslahti et al.
patent: 5677181 (1997-10-01), Parish
patent: 5753230 (1998-05-01), Brooks et al.
patent: 5766591 (1998-06-01), Brooks et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5874081 (1999-02-01), Parish
patent: 6123941 (2000-09-01), Bissell
patent: 6852318 (2005-02-01), Varner
patent: 0906919 (1999-04-01), None
patent: WO95/14714 (1995-06-01), None
patent: WO97/10507 (1997-03-01), None
patent: WO98/10795 (1998-03-01), None
patent: WO99/13329 (1999-03-01), None
Winter et al (TIPS, 1993, 14:139-143).
Baselga et al (J. Clin. Oncol, 1996, 14:737-744).
Chemicon (Mouse anti-human integrin alpha 5 beta 1 monoclonal antibody, 2002).
Chemicon (Mouse anti-human integrin CD94E monoclonal antibody, 2007).
Roitt et al (Immunology, 1993, Mosby, St. Louis, p. 6.4-6.5).
Gelboin (Pharmacological Review, 1993, 45:413-453).
Aota, S., Nomizu, M., and Yamada, K.M. 1994. The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J. Biol. Chem. 269: 24755-24761.
Arap W et al. 1997. Cancer Treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380.
Bader, B.L. et al. 1998. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all αv integrins. Cell 95: 507-519.
Bloch, W. et al. 1997. β1 Integrin is essential for teratoma growth and angiogenesis. J. Cell Biol. 139: 265-278.
Blystone, S.D. et al. 1994. Integrin ανβ3 differentially regulates adhesive and phagocytic functions of the fibronectin receptor α5β1. J. Cell Biol. 127: 1129-1137.
Brooks, P.C. et al. 1994a. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571.
Brooks, P.C. et al. 1994b. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164.
Brooks, P.C., et al. 1995. Anti-integrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96: 1815-1822.
Carron, C.P. et al.1998. A peptidomimetic antagonist of the Integrin ανβ3—inhibits Leydig cell tumor growth and development of hypercalcemia of malignancy. Cancer Res. 58: 1930-1955.
Castellani, P. et al. 1994. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer 59: 612-618.
Charo, If et al. 1990. The vitronectin receptor alpha v beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular attachment and spreading on fibronectin. J. Cell Biol. 111: 2795-800.
Christofidou-Solomidou, M. et al. 1997. Expression and function of endothelial cell αv integrin receptors in wound-induced human angiogenesis in human skin/SCID mice chimeras. Am. J. Path. 151: 975-983.
Clark, R.A.F. et al. 1982. Blood vessel fibronectin increases in conjunction with endothelial cell proliferation and capillary ingrowth during wound healing. J. Invest. Dermatol. 79: 269-276.
Clark, R.A.F. et al. 1996. Transient functional expression of ανβ3 on vascular cells during wound repair. Am. J. Path. 148: 1407-1421.
Collo, G. and Pepper, M.S. 1999. Endothelial cell integrin α5β1—expression is modulated by cytokines and during migration in vitro. J. Cell Sci. 112: 569-578.
Drake, C.J. et al. 1992. Antibodies to beta 1-integrins cause alterations of aortic vasculogenesis, in vivo. Dev. Dyn. 193: 83-91.
Drake, C.J. et al. 1995. An antagonist of integrin ανβ3 prevents maturation of blood vessels during embryonic neovascularization. J. Cell Science 108: 2655-2661.
Friedlander, M. et al. 1995. Definition of two angiogenic pathways by distinct alpha v integrins. Science 270:1500-1502.
Friedlander M. et al. 1996. Involvement of integrin ανβ3 and ανβ5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. 93: 9764-9769.
George, E. L., et al. 1993. Defects in mesodermal migration and vascular development in fibronectin-deficient mice. Development 119: 1079-1091.
Goh, K. L. et al. 1997. Mesodermal defects and cranial neural crest apoptosis in α5 integrin-null embryos. Development 124: 4309-4319.
Lan, N. et al. 1998. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J. Cell Sci.111: 3621-3631.
Kaczmarek, J. et al. 1994. Distribution of oncofetal fibronectin isoforms in normal hyperplastic and neoplastic human breast tissues. Int. J. Cancer 58: 11-16.
Koivunen, E. et al. 1993. Selection of peptides binding to the α5β1 integrin from a phage display library. J. Biol. Chem. 268: 20205-20210.
Koivunen, E., Wang, B., Ruoslahti, E. 1994. Isolation of a highly specific ligand for the α5β1 integrin from a phage display library. J. Cell Biol. 124: 373-380.
Magnusson, M.K. and Mosher, D.F. 1998. Fibronectin: Structure, assembly, and cardiovascular implications. Arterioscler. Thromb. Vasc. Biol. 18: 1363-1370.
Neri, D., Camemolla, B., Nissim, A., Blaza, E., Leprini, A., Querze, G., Pina, A., Tarli, L., Halin, C., Neri, P., Zardi, L. Winter, G. 1997. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin Isoform, Nature Biotech. 15: 1271-1275.
Pierschbacher, M.D., Hayman, EG; and Ruoslahti, E. 1981. Location of the cell-attachment site in fibronectin with monoclonal antibodies and proteolytic fragments of the molecule. Cell 26: 259-67.
Pytela, R. et al. 1985. Identification and isolation of a 140 kD cell surface glycoprotein with properties expected of a fibronectin receptor. Cell 40: 191-98.
Ruoslahti, E. et al. 1981. Alignment of biological active domains in the fibronectin molecule. J. Biol. Chem. 256:7277-81.
Sechler, J. L. and Schwartzbauer, J.E. 1998 Control of cell cycle progression by fibronectin matrix architecture. J. Biol. Chem. 273: 25533-25536.
Senger, D.R. et al. 1996. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphav beta3 integrin, osteopontin, and thrombin. Am. J. Pathol. 149:1-7.
Senger, D. R. et al. 1997. Angiogenesis promoted by vascular endothelial growth factors: Regulation through α1β1—and α2β1 integrins. Proc. Nat'l Acad. Sci. USA 94: 13612-13617.
Simon, K.O. et al. 1997. The ανβ3 integrin regulates α5β1-mediated cell migration toward fibronectin. J. Biol. Chem. 272: 29380-29389.
Stromblad S., et al. 1996. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest 98: 426-433.
Stromblad, S. and Cheresh, D. A. 1996. Integrins, angiogenesis and vascular cell survival. Chemistry and Biology 3: 881-885.
Suehiro,K., Gailit, J. and Plow, E.F. 1997. Fibrinogen is a ligand for integrin α5β1 on endothelial cells. J. Biol. Chem. 272: 5360-5366.
Varner, J.A. 1997. The role of vascular
Reddig Peter J.
The Regents of the University of California
Townsend and Townsend / and Crew LLP
Ungar Susan
LandOfFree
Methods for inhibiting angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3885863